Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

doi:10.1001/jamaoncol.2015.0617

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

JAMA oncology - 1 Sept 2015

Kadia Tapan M, Ravandi Farhad, Cortes Jorge, Kantarjian Hagop

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease in its clinical presentation, response to therapy, and overall prognosis. For decades, pretreatment karyotype evaluation has served to identify subgroups for risk-adapted postremission therapy, but the initial treatment approach has been largely unchanged. With continued advances in the genetic and epigenetic characterization of AML, we have discovered even...

Topics

Biomarkers, Tumor
Epigenesis, Genetic
Genetic Predisposition to Disease
Genetic Testing
Humans
Leukemia, Myeloid, Acute
Molecular Targeted Therapy
Mutation
Patient Selection
Phenotype
Precision Medicine
Predictive Value of Tests
Risk Assessment
Risk Factors
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 26181162
DOI: 10.1001/jamaoncol.2015.0617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics